Braftovi (encorafenib) + Erbitux (cetuximab) + Mektovi (binimetinib) Emerging Drug Insight and Market Forecast - 2032

“Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Braftovi is an oral small-molecule BRAF kinase inhibitor that targets a key enzyme in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, and others. Erbitux is a recombinant, human/mouse chimeric monoclonal antibody. The antibody binds to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. While Mektovi is an oral, small-molecule MEK inhibitor that targets key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumor cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR. In the US, Braftovi is approved in combination with cetuximab for metastatic colorectal cancer patients with a BRAF V600E mutation.

The clinical trial (BEACON CRC) was carried out for both Braftovi and Erbitux (dual combination) as well as triple combination therapy with Braftovi, Mektovi and cetuximab. However, so far, Braftovi in combination with cetuximab is approved in the US as well as in Europe, for the treatment of adult patients with mCRC with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy (i.e., in the second and third lines of therapy). BEACON CRC is the first and only phase III trial designed to test a BRAF/MEK combo targeted therapy in BRAFV600E-mutant mCRC (Pfizer, 2019).

On the other hand, in Japan, Ono Pharmaceutical obtained an approval of Braftovi and Mektovi for an additional indication of unresectable advanced or recurrent BRAF-mutant CRC that has progressed after chemotherapy, as well as in triplet combination therapy with Braftovi, Mektovi and cetuximab. This approval is related to the additional indication for a partial change in approved items of the manufacturing and marketing approval.

Currently, the companies are investigating the combination of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi in several clinical trials. Braftovi and cetuximab in combination with several chemotherapy agents are currently being evaluated as a first line of therapy for the treatment of mCRC (NCT04607421); along with that, the doublet combination of Braftovi and cetuximab is also being investigated as a first line of therapy. The company is also investigating the combination of encorafenib, binimetinib, and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease in a Phase II ANCHOR-CRC (NCT03693170) clinical trial.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib).
• The report contains forecasted sales of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) Analytical Perspective

In-depth Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) Market Assessment

This report provides a detailed market assessment of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib).

Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) Clinical Assessment

The report provides the clinical trials information of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer.
• This in-depth analysis of the forecasted sales data of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib)?
• What is the clinical trial status of the study related to Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) development?
• What are the key designations that have been granted to Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer?
• What are the forecasted sales of Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib) for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?

This product will be delivered within 2 business days.